Nucleosides - l pour le traitement des virus de l'hepatite b et epstein-bar

L-nucleosides for the treatment of hepatitis b-virus and epstein-bar virus

Abstract

A method for the treatment of a host, and in particular, a human, infected with HBV or EBV is provided that includes administering an HBV- or EBV-treatment amount of an L-nucleoside of formula(I) wherein R is a purine or pyrimidine base. In one preferred embodiment, the active compound is 2'-fluoro-5-methyl-.beta.-L-arabinofuranosyluridine (also referred to as L-FMAU). This compound is a potent antiviral agent against HBV and EBV and exhibits low cytotoxicity. Other specific examples of active compounds include N1-(2'-deoxy-2'-fluoro-.beta.-L-arabinofuranosyl)-5-ethyluracil, N1-(2'-deoxy-2'-fluoro-.beta.-L-arabinofuranosyl)-5-iodocytosine), and N1-(2'-deoxy-2'-fluoro-.beta.-L-arabinofuranosyl)-5-iodouracil.

Claims

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (0)

    Publication numberPublication dateAssigneeTitle

NO-Patent Citations (0)

    Title

Cited By (0)

    Publication numberPublication dateAssigneeTitle